Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)

Article ID	Journal	Published Year	Pages	File Type
8247312	International Journal of Radiation OncologyBiologyPhysics	2006	6 Pages	PDF

Abstract

Conclusion: Combined-modality therapy, based on high-dose methotrexate, results in improved survival outcomes in PCNSL. The risk of neurotoxicity for patients aged >60 years is unacceptable with this regimen, although survival outcomes for patients aged >60 years were higher than in many other series.

Keywords

Radiotherapy Neurotoxicity central nervous system Chemotherapy Lymphoma

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)

Authors

Peter C. (F.R.A.N.Z.C.R.), Daniel E. (F.R.A.N.Z.C.R.), Gary (F.R.A.N.Z.C.R.), K.-H. (F.R.A.N.Z.C.R.), Michael B. (F.R.A.N.Z.C.R.), Michael G. (F.R.A.N.Z.C.R.), Ian N. (F.R.A.C.P.), Grant E. (F.R.A.N.Z.C.R.),